Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort
Open Access
- 10 December 2020
- Vol. 70 (10), 2013-2015
- https://doi.org/10.1136/gutjnl-2020-323672
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea (NRF2019R1G1A109977912)
This publication has 9 references indexed in Scilit:
- Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysisGut, 2020
- A nationwide cohort study with propensity score matchingGut, 2020
- Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infectionDigestive and Liver Disease, 2020
- Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensusGut, 2020
- Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort studyThe Lancet Psychiatry, 2020
- Increased Risk of COVID-19 Among Users of Proton Pump InhibitorsThe American Journal of Gastroenterology, 2020
- Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort studyJournal of Allergy and Clinical Immunology, 2020
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matchingGut, 2020
- Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitisGut, 2019